Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criterion applicable to All Groups~* Subjects aged 2 to 17 years (inclusive) at enrollment~* weighing at least 13 Kg at the time of enrollment~Inclusion criterion applicable to Group A - Subjects at risk of meningococcal disease because of primary or secondary complement deficiencies~Inclusion criterion applicable to Group B~- Subjects at risk of meningococcal disease because of functional or anatomic asplenia~Inclusion criterion applicable to Group C - healthy subjects~Exclusion Criteria:~Exclusion criteria applicable to All Groups (A, B and C)~* History of any previous immunization with a meningococcal B vaccine~* History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine~* Known HIV infection~* History of any progressive or severe neurologic disorder or seizure disorder~* Contraindication to intramuscular injection or blood drawn~* Females who are pregnant, planning a pregnancy or nursing (breastfeeding)~* Females of childbearing potential who have not used or do not plan to use acceptable birth control measures~* History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects~Exclusion criterion applicable to Groups A and B~- Previous known or suspected disease caused by N. meningitidis in the last year.~Exclusion criteria applicable to Group C~* Previous known or suspected disease caused by N. meningitidis~* Known or suspected impairment/alteration of the immune system

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Complement deficiency
- Group B (Type: EXPERIMENTAL): asplenia/splenic dysfunction
- Group C (Type: ACTIVE_COMPARATOR): age-matched healthy controls

Based on this trial design, predict the completion outcome and termination type (if applicable).